Skip to content
A Green Sign – Lifestyle
Author:
BriaCell Therapeutics Corp.
BriaCell Presents Positive Clinical Data at ASCO 2026
June 1, 2026
BriaCell Therapeutics Announces Pricing of Offering
May 31, 2026
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
May 26, 2026
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
May 22, 2026
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
May 15, 2026
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
May 14, 2026
BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
May 13, 2026
BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
May 12, 2026
BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
May 7, 2026
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
May 6, 2026
1
2
Next Page
→